Effect of Non-Invasive Neuromodulation on Primary Chronic Pain, Including Post-COVID-19
NCT ID: NCT06689345
Last Updated: 2024-11-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
NA
55 participants
INTERVENTIONAL
2024-04-21
2024-12-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study will be organized as the following: It will begin with an assessment, divided into a part with questionnaires and another with specific tests. The questionnaires are aimed at understanding volunteer's characteristics, pain, fatigue, inflammation, sleep, quality of life, and the presence of symptoms of anxiety and depression. Next, the volunteer will undergo two tests to assess the behavior of his/her brain. They are performed using EEG electroencephalography and transcranial magnetic stimulation (TMS).
* Quantitative EEG at rest - In this technique, a cap with electrodes is placed on volunteer's head, in contact with hair, which are connected through a gel. The volunteer needs to remain still for 6 minutes with eyes closed, sitting in a comfortable chair.
* TMS with EEG - First, the volunteer will be asked to honestly answer the questions in the safety questionnaire for using this technique. Honest answers will eliminate the risks associated with this evaluation. Next, the volunteer's skin will be cleaned with alcohol and a special paste and place three self-adhesive electrodes on the muscle of the volunteer's hand, in a muscle called the interosseous, on the side where he/she writes. These electrodes will only capture the electrical activity of the muscle. Next, a series of magnetic pulses will be administered to the volunteer's skull, in the area that controls the hand muscle. It will contract with each pulse and, with this, so that the functioning of this connection can be understood. At the same time, the EEG device will capture the brain activities that occur during this TMS stimulation. During this exam, the volunteer may feel anything from no stimulation to muscle contractions that move his/her hand. Some people also experience redness under the electrodes, fatigue, or muscle/joint pain.
After the assessments, volunteers will be randomly selected to receive neuromodulation sessions using low-intensity electrical stimulation of the vagus nerve, using electrodes in the outer ear (active group), or sessions that only simulate this neuromodulation (sham, or placebo, group). This will occur for five consecutive days, starting on the day of the assessment. This stimulation is very weak and may not even be felt by the person receiving it. This technique is safe and the most that may occur is redness or itching of the skin. A few people may also experience tingling, a burning sensation or momentary local pain, fatigue, drowsiness, difficulty concentrating and a feeling of nervousness during or after the stimulation.
At the end of the 5 days of electrical stimulation, the same initial assessments will be repeated to see if anything has changed in the volunteer's brain, heart rate, blood pressure, pain, fatigue, inflammation, sleep, quality of life, depression, and anxiety.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
rTMS Effects in the Neuromodulation and Pain Threshold of Chronic Myofascial Pain Patients
NCT01964729
Repetitive Transcranial Magnetic Stimulation in Central Neuropathic Pain
NCT02386969
Effects of Repetitive Transcranial Magnetic Stimulation on Heart Rate Variability
NCT03739489
tDCS in the Management of Post-COVID Disorders
NCT06074848
Repetitive Transcranial Magnetic Stimulation of Relief of Fibromyalgia Pain
NCT03658694
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
Then, we will test the effect of neuromodulation through, vagal stimulation, on pain, fatigue, mental healthy and disautonomy of people with primary chronic pain and/or post-COVID syndrom. For this, active and sham stimulations will be compared.
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthy subjects
Once a week, each subject will receive a random stimulation in one of the following areas: (i) the afferent portion of the vagal nerve on the Cymba Conchae of the left ear (taVNS); (ii) rPMS on an efferent portion of the vagal nerve on the neck; (iii) rTMS intermittent theta- burst on the left DLPFC; (iv) simulated taVNS (SHAM) on helix left ear or.
taVNS - transauricular vagal nerve stimulation
30 minutes of electrical stimulation on the afferent portion of the vagal nerve on the cymba conchae of the ear, in the following configuration: 30 seg ramp up, 30 seg on, 30 seg off in intensity on which the volunteer feels a light tingling.
rPMS - repetitive peripheric magnetic stimulation
Magnetic stimulation on the efferent portion of the vagal nerve on the neck, on the following configuration: 20Hz, 25 pulses in the trein, in every inhalation, for 20 inhalations with 50% of machine capacity (500 pulses total).
rTMS - repetitive transcranial magnetic stimulation
rTMS intermitent theta- burst on the left DLPFC, on the following configuration: 50 Hz in treins of 5Hz, with 110% of the resting motor limiar and 600 pulses in 3 minutes.
taVNS sham
Simulated taVNS (SHAM) on helix left ear, that is the same as taVNS, but during only 1 minute
Chronic Pain and post Covid Syndrom - Active
These volunteers will receive 30 minutes of taVNS on the afferent portion of the vagal nerve on the ears.
taVNS - transauricular vagal nerve stimulation
30 minutes of electrical stimulation on the afferent portion of the vagal nerve on the cymba conchae of the ear, in the following configuration: 30 seg ramp up, 30 seg on, 30 seg off in intensity on which the volunteer feels a light tingling.
Chronic Pain and post Covid Syndrom - Sham
These volunteers will receive 30 minutes of simulated taVNS on the afferent portion of the vagal nerve on the ears. For this, the equipment will be programmed to be on only for 1 minute.
taVNS sham
Simulated taVNS (SHAM) on helix left ear, that is the same as taVNS, but during only 1 minute
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
taVNS - transauricular vagal nerve stimulation
30 minutes of electrical stimulation on the afferent portion of the vagal nerve on the cymba conchae of the ear, in the following configuration: 30 seg ramp up, 30 seg on, 30 seg off in intensity on which the volunteer feels a light tingling.
rPMS - repetitive peripheric magnetic stimulation
Magnetic stimulation on the efferent portion of the vagal nerve on the neck, on the following configuration: 20Hz, 25 pulses in the trein, in every inhalation, for 20 inhalations with 50% of machine capacity (500 pulses total).
rTMS - repetitive transcranial magnetic stimulation
rTMS intermitent theta- burst on the left DLPFC, on the following configuration: 50 Hz in treins of 5Hz, with 110% of the resting motor limiar and 600 pulses in 3 minutes.
taVNS sham
Simulated taVNS (SHAM) on helix left ear, that is the same as taVNS, but during only 1 minute
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of primary chronic pain (for more than 3 months), such as fibromyalgia (chronic widespread pain), primary chronic headache and orofacial pain, chronic primary visceral pain, post-COVID pain, and chronic primary musculoskeletal pain;
* In the case of post-COVID-19 pain, the symptoms must be present for at least 12 weeks. The complaints of pain, fatigue, and/or changes in mental health should have started after infection by SARS-Cov-2.
Exclusion Criteria
* obese individuals with a high abdominal fat index characterized by a waist/hip ratio of 0.80 for women and 0.95 for men;
* heart disease;
* diabetes mellitus;
* vestibular alterations characterized by the Dix-Hallpike maneuver, supine rotation test, arc test, side-lying maneuver, and post-head-shake nystagmus;
* diagnosis of epilepsy or first-degree family history of epilepsy
* fever;
* chronic consumption of alcohol, or other recreational drugs;
* presence of contraindications for the use of non-invasive neuromodulation;
* those who become ill with COVID-19 during the data collection period;
* those who are unable to answer the evaluation questionnaires;
* those with clinical instability;
* those who have a previous history of chronic pain or fatigue before contracting COVID-19;
* those who have neuropathic pain.
18 Years
64 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Sao Paulo
OTHER
Coordination for the Improvement of Higher Education Personnel
OTHER
Federal University of ABC
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tiago S Lopes, PhD
Role: STUDY_CHAIR
Federal University of ABC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Federal University of ABC
Sâo Bernardo Do Campo, São Paulo, Brazil
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
U1111-1293-2751
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.